Spark Provides Trial Updates for Investigational Gene Therapy SPK-8011
Spark Therapeutics recently announced updates from an ongoing phase 1/2 clinical trial of SPK-8011, the company’s investigational gene therapy candidate for hemophilia A. Administered via a one-time intravenous infusion, SPK-8011 is designed to…
NHF Announces New Partnership with InSourceRx
FOR IMMEDIATE RELEASE Media Contact Ilana Ostrin iostrin@hemophilia.org 212-328-3769 NHF Announces New Partnership with InSourceRx A portion of proceeds from InSourceRx will benefit NHF New York, NY - InSourceRx, a Nebraska-based…
Nora Ancel
Thomas Brand
Lisa Nick
Stephanie Simpson
Deb Weiner
Shelley Crisp
Mariel Laueano
A Retrospective Study Evaluating Immune Tolerance Induction (ITI) with a Plasma-derived Factor VIII for Patients with Hemophilia A and High Titer Inhibitor
Objective: The formation of inhibitors to clotting factors is a serious complication in hemophilia A. Immune tolerance induction (ITI) therapy remains the primary method for eradicating inhibitors. This multicenter retrospective…